Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive Biomarkers, Surrogate Endpoints), By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2023 - 2030
Biomarker Clinical Phase Outsourcing Services Market Growth & Trends
The global biomarker clinical phase outsourcing services market size is expected to reach USD 27.17 billion by 2030, registering a CAGR of 20.6%, according to a new report by Grand View Research, Inc. Increasing diagnostic applications of biomarkers, rapid advancements in OMICS technologies, a rise in research and development (R&D) funding from the government, and the shift toward precision medicine are a few of the factors driving the growth of the market.
The market is fragmented, with several key players having similar technological and processing capabilities. These companies offer various services related to biomarker testing, including assay development, sample analysis, data interpretation, and clinical trial support. This industry is characterized by intense competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.
Biomarkers are at the core of personalized medicine, enabling better patient care and more effective treatments. Hence, the shift towards precision medicine is another significant factor supporting demand for biomarker testing services, thereby augmenting market growth. For instance, in January 2022, Pfizer Inc. and Beam Therapeutics Inc. announced an exclusive four-year research collaboration agreement to develop precision medicines for rare genetic diseases.
The COVID-19 pandemic moderately impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving biomarker testing services. However, the market recovered from the losses due to the rapid development of biomarkers for COVID-19 diagnosis. Biomarker-based tests, such as PCR assays targeting viral RNA and antigen tests detecting viral proteins, have been crucial for identifying and tracking the virus.
Biomarker Clinical Phase Outsourcing Services Market Report Highlights
- Based on biomarker type, the surrogate endpoints segment accounted for the largest share of 56.0% in 2022. The segment’s growth is driven by the growing demand for precision medicines and the rise in the number of clinical trials involving the use of biomarker analysis
- Based on therapeutic area, the oncology segment accounted for the largest share of 34.6% in 2022. High segment shares are majorly due to the increasing demand for cancer biomarkers for early detection and diagnosis of the condition
- Based on end-use, the biotechnology companies are anticipated to witness the highest CAGR of 20.8% across the analysis timeframe due to the increasing number of biopharmaceutical companies investing in developing novel biomarker testing services
- Asia Pacific is anticipated to witness the highest CAGR of 21.4% during the forecast time frame. High growth is primarily due to increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India
- Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment Definitions
- 1.1.2. Biomarker Type
- 1.1.3. Therapeutic Area
- 1.1.4. End-use
- 1.2. Regional Scope
- 1.3. Estimates And Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective-1
- 1.4.2. Objective-2
- 1.4.3. Objective-3
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR’s Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. Parent Market Analysis
- 1.10. List Of Secondary Sources
- 1.11. List Of Abbreviations
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Biomarker Clinical Phase Outsourcing Services Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing diagnostic applications of biomarkers
- 3.2.1.2. Rise in R&D funding from the government
- 3.2.1.3. Rapid advancements in technologies such as genomics, proteomics, and imaging
- 3.2.1.4. The shift toward precision medicine
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High capital investment
- 3.2.2.2. Challenges related to quality control
- 3.3. Biomarker Clinical Phase Outsourcing Services Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat Of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- Chapter 4. Biomarker Clinical Phase Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis
- 4.1. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Segment Dashboard
- 4.2. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Movement Analysis
- 4.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2018 - 2030
- 4.3.1. Predictive Biomarkers
- 4.3.1.1. Predictive Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 4.3.2. Prognostic Biomarkers
- 4.3.2.1. Prognostic Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 4.3.3. Safety Biomarkers
- 4.3.3.1. Safety Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 4.3.4. Surrogate Endpoints
- 4.3.4.1. Surrogate Endpoints Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- Chapter 5. Biomarker Clinical Phase Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis
- 5.1. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
- 5.2. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Movement Analysis
- 5.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
- 5.3.1. Oncology
- 5.3.1.1. Oncology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.2. Neurology
- 5.3.2.1. Neurology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.3. Cardiology
- 5.3.3.1. Cardiology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.4. Autoimmune Diseases
- 5.3.4.1. Autoimmune Diseases Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- 5.3.5. Others
- 5.3.5.1. Others Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
- Chapter 6. Biomarker Clinical Phase Outsourcing Services Market: End-use Estimates & Trend Analysis
- 6.1. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Segment Dashboard
- 6.2. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Movement Analysis
- 6.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By End-use, 2018 - 2030
- 6.3.1. Pharmaceutical Companies
- 6.3.1.1. Pharmaceutical Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
- 6.3.2. Biotechnology Companies
- 6.3.2.1. Biotechnology Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
- 6.3.3. Others
- 6.3.3.1. Others Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
- Chapter 7. Biomarker Clinical Phase Outsourcing Services Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2022 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. North America
- 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key Country Dynamics
- 7.5.1.2. Competitive Scenario
- 7.5.1.3. Regulatory Framework
- 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
- 7.5.2. Germany
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
- 7.5.3. France
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
- 7.5.4. Italy
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
- 7.5.5. Spain
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
- 7.5.6. Denmark
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
- 7.5.7. Sweden
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
- 7.5.8. Norway
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key Country Dynamics
- 7.6.1.2. Competitive Scenario
- 7.6.1.3. Regulatory Framework
- 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
- 7.6.2. India
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
- 7.6.4. South Korea
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
- 7.6.6. Thailand
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key Country Dynamics
- 7.7.1.2. Competitive Scenario
- 7.7.1.3. Regulatory Framework
- 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
- 7.7.2. Mexico
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key Country Dynamics
- 7.8.1.2. Competitive Scenario
- 7.8.1.3. Regulatory Framework
- 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
- 7.8.3. UAE
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
- 7.8.4. Kuwait
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.1.1. Innovators
- 8.1.2. Market Leaders
- 8.1.3. Emerging Players
- 8.1.4. Company Market Share Analysis, 2022
- 8.2. Company Profiles
- 8.2.1. Laboratory Corporation of America Holdings
- 8.2.1.1. Company Overview
- 8.2.1.2. Financial Performance
- 8.2.1.3. Service Benchmarking
- 8.2.1.4. Strategic Initiatives
- 8.2.2. Parexel International Corporation
- 8.2.2.1. Company Overview
- 8.2.2.2. Financial Performance
- 8.2.2.3. Service Benchmarking
- 8.2.2.4. Strategic Initiatives
- 8.2.3. ICON plc
- 8.2.3.1. Company Overview
- 8.2.3.2. Financial Performance
- 8.2.3.3. Service Benchmarking
- 8.2.3.4. Strategic Initiatives
- 8.2.4. Charles River Laboratories
- 8.2.4.1. Company Overview
- 8.2.4.2. Financial Performance
- 8.2.4.3. Service Benchmarking
- 8.2.4.4. Strategic Initiatives
- 8.2.5. Proteome Sciences
- 8.2.5.1. Company Overview
- 8.2.5.2. Financial Performance
- 8.2.5.3. Service Benchmarking
- 8.2.5.4. Strategic Initiatives
- 8.2.6. Fujirebio
- 8.2.6.1. Company Overview
- 8.2.6.2. Financial Performance
- 8.2.6.3. Service Benchmarking
- 8.2.6.4. Strategic Initiatives
- 8.2.7. WuXi AppTec
- 8.2.7.1. Company Overview
- 8.2.7.2. Financial Performance
- 8.2.7.3. Service Benchmarking
- 8.2.7.4. Strategic Initiatives
- 8.2.8. NorthEast BioAnalytical Laboratories LLC.
- 8.2.8.1. Company Overview
- 8.2.8.2. Financial Performance
- 8.2.8.3. Service Benchmarking
- 8.2.8.4. Strategic Initiatives
- 8.2.9. Celerion
- 8.2.9.1. Company Overview
- 8.2.9.2. Financial Performance
- 8.2.9.3. Service Benchmarking
- 8.2.9.4. Strategic Initiatives
- 8.2.10. GenScript ProBio
- 8.2.10.1. Company Overview
- 8.2.10.2. Financial Performance
- 8.2.10.3. Service Benchmarking
- 8.2.10.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook